Phase III Randomized Study of Induction Therapy Comparing Daunorubicin With Idarubicin Followed By Consolidation Therapy Comparing High-Dose Cytarabine With Sequential Multiagent Chemotherapy in Patients With Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study)

Authors
Category Primary study
JournalUMIN Clinical Trials Registry
Year 2005
INTERVENTION: Daunorubicin Idarubicin High‐Dose Cytarabine Sequential Multiagent Chemotherapy CONDITION: Acute Myeloid Leukemia PRIMARY OUTCOME: Complete remission rate in induction therapy Relapse‐free survival SECONDARY OUTCOME: Overall survival Toxicity more than grade 2 INCLUSION CRITERIA: 1. Newly diagnosed AML (except M3) 2. PS 0‐3 (ECOG) 3. Adequate hepatic, renal, pulmonary and cardiac function 4. Written informed consent
Epistemonikos ID: a13b90d2a331bb2f73300d9769dd7a2a1070e272
First added on: Aug 21, 2024